Brief Introduction

Jiangsu Jibeier Pharmaceutical Co., Ltd. was established in November 2001 and registered in Zhenjiang, Jiangsu Province. The company is a high-tech enterprise specialized in drug R & D and manufacture and has formed a diversified product series mainly composed of high-tech products, such as Leucogen Tablets for leukogenic effect, and Nitrendipine and Atenolol Tablets, first class new combination drug for anti hypertension, etc. Jibeier is committed to developing innovative drugs for the treatment of depression, cancer, stomach disease and other diseases.

The company has established a professional R & D team of more than 100 people. It has built a research and development technology platform supported by combination preparation research and development technology, deuterium drug research and development technology, and liposome drug research and development technology, and has started a series of innovative drug research and development work. At present, the company has established "Jiangsu academician workstation", "Jiangsu anti lung cancer and breast cancer Engineering Research Center" and other research and development centers. It has been authorized 12 national invention patents, 1 U.S. patent, and 15 patents are being reviewed; it has obtained 6 new drug certificates, 6 high-tech product certificates and 2 national key new product certificates. Jibeier also participated in the drafting of the national drug quality standard of Leucogen Tablets, Nitrendipine and Atenolol Tablets, Aceclofenac enteric-coated Tablets and other products.

Company Overview

Full name Jiangsu Jibeier Pharmaceutical Co., Ltd.
Abbreviations Jibeier Pharmaceutical
Code 688566
Founded 2001-11-13
Listing 2020-05-18
Domicile Zhenjiang City, Jiangsu Province
STAR Theme Biomedicine
CSRCSector Manufacturing
Has weighted voting rights structure? No



  2019 2018 2017
Earnings Per Share 0.81 0.69 0.55
R&D expenditure as a % of operating revenue 5.74% 4.04% 3.79%
Operating Revenue 542.52 484.96 452.33
Net Income 112.78 96.92 77.61

Income Statement (Unit: RMB mn)

  2019 2018 2017
Operating Revenue 542.52 484.96 452.33
Operating Costs 63.89 64.17 67.20
Operating Income 130.06 114.22 93.04
Pretax Income 129.78 113.24 92.44
Income Tax 17.00 16.33 14.83
Net Income 112.78 96.92 77.61

Balance Sheet(Unit: RMB mn)

  2019 2018 2017
Current Assets-Total 365.44 272.89 329.36
Non-current Assets-Total 230.18 205.11 198.31
Total Assets 595.62 477.99 527.68
Current Liabilities-Total 65.09 61.26 52.12
Non-current Liabilities-Total 60.07 59.06 34.80
Total Liabilities 125.16 120.32 86.92
Stockholder's Equity
Share Capital 140.21 140.21 140.21
Retained Profits 284.22 171.30 254.69
Total Owners' Equity 470.46 357.68 440.76

Cash Flow Statement (Unit: RMB mn)

  2019 2018 2017
Net Cash Flows-Operating 115.45 97.97 111.66
Net Cash Flows-Investing -29.55 -5.29 -19.58
Net Cash Flows-Financing -17.42 -169.14 -24.02

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
镇江中天投资咨询有限责任公司 54.40 38.80%
南通汇瑞投资有限公司 27.20 19.40%
耿仲毅 24.61 17.55%
胡涛 17.68 12.61%
南通汇祥投资咨询有限公司 16.32 11.64%
合计 140.21 100%

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.